Bartonella spp. infection has been reported in association with an expanding spectrum of symptoms and lesions. Among 296 patients examined by a rheumatologist, prevalence of antibodies against *Bartonella henselae*, *B. koehlerae*, or *B. vinsonii* subsp. *berkhoffii* (185 [62%]) and *Bartonella* spp. bacteremia (122 [41.1%]) was high. Conditions diagnosed before referral included Lyme disease (46.6%), arthralgia/arthritis (20.6%), chronic fatigue (19.6%), and fibromyalgia (6.1%). *B. henselae* bacteremia was significantly associated with prior referral to a neurologist, most often for blurred vision, subcortical neurologic deficits, or numbness in the extremities, whereas *B. koehlerae* bacteremia was associated with examination by an infectious disease physician. This cross-sectional study cannot establish a causal link between *Bartonella* spp. infection and the high frequency of neurologic symptoms, myalgia, joint pain, or progressive arthropathy in this population; however, the contribution of *Bartonella* spp. infection, if any, to these symptoms should be systematically investigated.

The genus *Bartonella* comprises at least 26 species or subspecies of vector-transmitted bacteria, each of which has evolved to cause chronic bacteremia in >1 mammalian reservoir hosts (1–4). Among these, *bartonellae* of 14 species or subspecies have been implicated in zoonotic diseases (5,6), including cat-scratch disease, which is caused by *B. henselae* transmission during a cat bite or scratch and characterized by acute onset of self-limiting fever and regional lymphadenopathy (7–9). Recent observations, however, are causing a paradigm shift from the assumption that infection with a *Bartonella* sp. consistently induces an acute, self-limiting illness to the realization that subsets of infected, immunocompetent patients can become chronically bacteremic (10–15).

After *B. henselae* was confirmed as the primary cause of cat-scratch disease in the early 1990s, several reports described an association between the newly identified bacterium and rheumatic disease manifestations, variously described as rheumatoid, reactive, or chronic progressive polyarthristis (16–20). One study, however, failed to isolate *B. henselae* from synovial fluid of 20 patients with chronic arthritis (21). Because epidemiologic evidence supports an association between rheumatic symptoms and cat-scratch disease and because arthritis is a primary disease manifestation of *Borellia burgdorferi* infection (Lyme disease), we explored whether antibodies against and bacteremia with *Bartonella* spp. can be detected in patients examined for arthropathy or chronic myalgia. Our primary objective was to determine the serologic and molecular prevalence of *Bartonella* spp. bacteremia in patients referred to a clinical rheumatologist. We also compared self-reported symptoms, health history, and demographic factors with *Bartonella* spp. bacteremia as determined by an enrichment blood culture platform combined with PCR amplification and DNA sequencing, when possible, to determine the *Bartonella* species and strain. This study was conducted in conjunction with North Carolina State University Institutional Review Board approval (IRB# 164–08–05).
Materials and Methods

Study Population

For this cross-sectional study, we enrolled only patients examined by a rheumatologist in the Maryland–Washington, DC, USA, area from August 25, 2008, through April 1, 2009. Because Bartonella spp. are known to primarily infect cells within the vascular system, including erythrocytes, endothelial cells, and potentially circulating and tissue macrophages (1,5,6), selection was biased by patients who had historical, physical examination, or laboratory evidence of small vessel disease, including a subset of patients with a prior diagnosis of Lyme disease or chronic post–Lyme syndrome. We also included patients with chronic joint pain, prior documentation of synovial vascular inflammation, or a diagnosis of rheumatoid arthritis.

A standardized 5-page questionnaire was mailed to each participant for self-report. The questionnaire collected information about demographics, animal/arthropod exposure, history of visiting a medical specialist, outdoor activity, self-reported clinical symptoms, and concurrent conditions. Questionnaires were returned to the Intracellular Pathogens Research Laboratory at North Carolina State University, College of Veterinary Medicine, Raleigh, North Carolina, USA, where results were entered into an electronic database.

Sample Collection

From each patient, the attending rheumatologist aseptically obtained anticoagulated blood samples (in EDTA tubes) and serum samples and shipped them overnight to the laboratory. Patient variations included timing of sample collection relative to onset of illness, duration of illness, current illness severity, and prior or recent use of antimicrobial drugs. The samples were then processed in a limited-access laboratory.

Sample Processing

Immunofluorescence Antibody Assay

To determine the antibody titer to each Bartonella species or subspecies, we used B. henselae, B. koehlerae, and B. vinsonii subsp. berkhoffii (genotypes I, II, and III) antigens in a traditional immunofluorescence antibody (IFA) assay with fluorescein conjugated goat anti-human IgG (Pierce Antibody; Thermo Fisher Scientific), air dried, acetone fixed, frozen, and stored. Serum samples were diluted in a phosphate-buffered saline solution containing normal goat serum, Tween-20, and powdered nonfat dry milk to block nonspecific antigen binding sites and then incubated on antigen slides. All available patient serum was screened at dilutions from 1:16 to 1:64. Samples reactive at a 1:64 dilution were further tested with 2-fold dilutions to 1:8192. As in previous studies, we defined a seroreactive antibody response against a specific Bartonella sp. antigen as a threshold titer of 64 (10–15,23,24).

Bartonella α Proteobacteria Growth Medium

Enrichment Culture

Each sample was tested by PCR amplification of Bartonella spp. DNA before and after enrichment of blood and serum in Bartonella α Proteobacteria growth medium (BAPGM) (10–14,23–26). The BAPGM platform incorporates 4 PCR steps, representing independent components of the testing process for each sample, as follows: step 1) PCR amplifications of Bartonella spp. after DNA extraction from whole blood and serum; steps 2 and 3) PCR after whole blood culture in BAPGM for 7 and 14 days; and step 4) PCR of DNA extracted from subculture isolates (if obtained after subinoculation from the BAPGM flask at 7 and 14 days onto plates containing trypticase soy agar with 10% sheep whole blood, which are incubated for 4 weeks). To avoid DNA carryover, we performed PCR sample preparation, DNA extraction, and PCR amplification and analysis in 3 separate rooms with a unidirectional work flow. All samples were processed in a biosafety cabinet with HEPA (high-efficiency particulate air) filtration in a limited-access laboratory.

Methods used to amplify Bartonella DNA from blood, serum, and BAPGM liquid culture and subculture samples included conventional PCR with Bartonella genus primers targeting the 16S-23S intergenic spacer region (ITS) and a second PCR with B. koehlerae ITS species-specific primers, as described (13,25–29). Amplification of the B. koehlerae ITS region was performed by using oligonucleotides Bkoehl-1s: 5′-CTT CTA AAA TAT CGC TTC TAA AAA TTG GCA TGC-3′ and Bkoehl125as: 5′-GCC TTT TTT GGT GAC AAC CAC TTT TCT TAA G-3′ as forward and reverse primers, respectively. Amplification was performed in a 25-μL final volume reaction containing 12.5 μL of Tak-Ex Premix (Fisher Scientific), 0.1 μL of 100 μM of each forward and reverse primer (IDT; DNA Technology, Dark native...
Coralville, IA, USA), 7.3 μL of molecular grade water, and 5 μL of DNA from each sample tested.

Conventional PCR was performed in an Eppendorf Mastercycler EPgradient (Hauppauge, NY, USA) under the following conditions: 1 cycle at 95°C for 2 s, followed by 55 cycles with DNA denaturing at 94°C for 15 s, annealing at 64°C for 15 s, and extension at 72°C for 18 s. The PCR was completed by a final cycle at 72°C for 30 s. As previously described for the Bartonella ITS genus and B. koehlerae-specific PCRs, all products were analyzed by using 2% agarose gel electrophoresis and ethidium bromide under UV light, after which amplicon products were submitted to a commercial laboratory (Eton Bioscience Inc., Research Triangle Park, NC, USA) for DNA sequencing to identify the species and ITS strain type (13,15,28,30).

To check for potential contamination during processing, we simultaneously processed a noninoculated BAPGM culture flask in the biosafety hood in an identical manner for each batch of patient blood and serum samples tested. For PCR, negative controls were prepared by using 5 μL of DNA from the blood of a healthy dog. All controls remained negative throughout the course of the study.

Statistical Analysis

Descriptive statistics were obtained for all demographic variables, self-reported clinical symptoms and concurrent conditions, previous specialist consultation, and self-reported exposures. The χ² test was used to assess associations between self-reported clinical symptoms and previous specialist consultation separately with PCR results for B. henselae; B. koehlerae; and B. vinsonii subsp. berkhoffii genotypes I, II, and III. The Fisher exact test was used when expected cell value was <5. For the initial analysis, a liberal α value (α=0.10) was selected. The effect of each significant variable on the outcome variables was adjusted in separate multivariate logistic regression models controlling for age, sex, and health status. The models were repeated for different possible outcomes: PCR results for B. henselae or PCR results for B. koehlerae. Variables maintaining p<0.05 were considered significant. For some comparisons of potential interest, we were unable to estimate associations with the outcome(s) of interest because of low numbers (e.g., B. vinsonii subsp. berkhoffii genotypes I, II and III). Statistical analyses were performed by using SAS/STAT for Windows version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results

Patient Characteristics

The age range of the 296 patients was 3–90 years; median ages were 46 years for women and 36 years for men (Table 1). Women made up ≈70% of the study population. Most (68.2%) patients reported that they felt ill, whether chronically or infrequently, and 27.7% considered themselves to be generally healthy. The most common animal exposure reported was dog (n = 252; 85.1%), followed by cat (n = 202; 68.2%) and horse (n = 86; 29.0%). Most patients reported having been bitten or scratched by an animal (n = 202; 68.2%) or exposed to ticks (n = 229; 77.4%) and biting flies (n = 160; 54.0%). Hiking was the predominant outdoor activity reported (52.0%). Most (273 [92.2%]) patients reported having had a condition diagnosed before visiting the rheumatologist. Previously diagnosed conditions included Lyme disease (46.6%), arthralgia/arthritis or osteoarthritis/rheumatoid arthritis (20.6%), chronic fatigue (19.6%), and fibromyalgia (6.1%) (Figure 1).

Serologic and BAPGM Findings

Of the 296 patients, 185 (62.5%) were seroreactive to ≥1 Bartonella sp. antigens and 122 (41.1%) were infected with B. henselae, B. koehlerae, B. vinsonii subsp. berkhoffii, or Bartonella spp. Of the 122 patients with Bartonella spp. infection, PCR results were positive but DNA sequencing was unsuccessful or did not enable species identification for 29 (23.7%). After subculture, 6 isolates were obtained from 5 samples: 3 B. henselae isolates, 2 B. koehlerae isolates, and 1 Bartonella sp. isolate that was not fully characterized. Of the Bartonella-infected patients, 120 (98.4%) had a positive PCR result after DNA extraction from blood, serum, or enrichment culture (Figure 2), and 2 (1.6%) had a positive PCR result only after subculture isolation.

For B. henselae, 67 (22.6%) patients were seroreactive and 40 (13.5%) had positive PCR results. Of these 40 patients, only 7 (17.5%) were concurrently B. henselae seroreactive, whereas 33 (82.5%) patients who had a positive PCR result were not seroreactive to B. henselae antigens. There was no association between B. henselae antibodies and bacteremia (p = 0.37).

For B. koehlerae, 89 (30.1%) patients were seroreactive and 54 (18.2%) had positive PCR results. Of these 54 patients, 24 (44.4%) were seroreactive to B. koehlerae by IFA assay, whereas 29 (53.6%) were not seroreactive to B. koehlerae antigens. One patient with a positive B. koehlerae PCR result did not have a concurrent IFA test result (serum not submitted). There was an association between B. koehlerae seroreactivity and bacteremia (p = 0.008); seroreactive patients were more likely to be infected (odds ratio [OR] 2.25 [1.22–4.15]).

For B. vinsonii subsp. berkhoffii, 148 (50.0%) patients were seroreactive by IFA testing to at least 1 of 3 genotypes, and 10 (3.4%) had a positive PCR. Of these 10 patients, 3 were infected with genotype I, 6 were infected with genotype II, and for 1 patient the genotype could...
not be defined on the basis of readable DNA sequence. Seroreactivity to genotypes I, II, and III was found for 77 (26.0%), 102 (34.5%), and 82 (27.7%) patients, respectively. There was no association between B. vinsonii subsp. berkhoffii seroreactivity and bacteremia. Combined PCR and IFA assay results are summarized in Table 2. Of the patients with a positive PCR, 65% reported a prior diagnosis of Lyme disease (n = 138), bartonellosis (n = 29), or babesiosis (n = 14). Among the 138 patients with a prior diagnosis of Lyme disease, the prevalence of Bartonella

Table 1. Characteristics and Bartonella spp. PCR results for 296 patients examined by a rheumatologist, Maryland–Washington, DC, USA, August 25, 2008–April 1, 2009*

| Characteristic                  | Overall study population, no. (%) | Overall positive Bartonella spp. result by PCR, no. (%) | Bartonella spp.t |
|--------------------------------|-----------------------------------|--------------------------------------------------------|----------------|
|                                | 296 (100)                         | 122 (41.4) 40 (13.5) 54 (18.2) 10 (3.4) 29 (9.8)      |                |
|                                | Sex                               | F 205 (69.3) 86 (29.0) 24 (11.7) 38 (18.5) 7 (3.4) 21 (10.3) |
|                                | M 91 (30.7)                       | 36 (12.2) 16 (17.6) 16 (17.5) 3 (3.3) 8 (8.8)         |                |
|                                | State of residence                | Maryland 148 (50.0) 58 (39.2) 20 (13.5) 27 (18.2) 5 (3.4) 13 (8.8) |
|                                | Virginia 76 (25.7)                | 37 (48.7) 13 (17.1) 19 (25.0) 0 7 (9.2)               |                |
|                                | Pennsylvania 26 (8.8)             | 9 (34.6) 2 (7.7) 3 (11.5) 2 (7.7) 3 (11.5)            |                |
|                                | District of Columbia 16 (5.4)     | 5 (31.3) 1 (6.3) 1 (6.3) 1 (6.3) 2 (12.5)             |                |
|                                | Other 30 (10.1)                   | 13 (43.3) 4 (13.3) 4 (13.3) 2 (6.7) 4 (13.3)          |                |
|                                | Immunofluorescence antibody results | All Bartonella spp. 185 (62.5) 77 (41.6) 25 (13.5) 33 (17.8) 4 (2.1) 20 (10.8) |
|                                | B. henselae 67 (22.6)             | 24 (35.8) 7 (10.3) 8 (11.7) 2 (2.9) 8 (11.7)            |                |
|                                | B. koehlerae 89 (30.1)            | 38 (42.7) 10 (11.2) 24 (26.9) 3 (3.4) 5 (5.6)            |                |
|                                | B. vinsonii subsp. berkhoffii 148 (50.0) 59 (39.8) 21 (14.1) 21 (14.1) 3 (2.0) 18 (12.1) |
|                                | Self-report health assessment      | Healthy 82 (27.7) 32 (39.0) 12 (14.6) 13 (15.8) 3 (3.6) 7 (8.5) |
|                                | No 13 (4.4)                       | 6 (46.2) 2 (15.4) 3 (23.1) 1 (7.7) 2 (15.4)            |                |
|                                | Animal contact                    | Dog 252 (85.1) 104 (41.3) 33 (13.1) 45 (17.9) 7 (2.8) 27 (10.7) |
|                                | No 3 (1.0)                        | 2 (66.7) 1 (33.3) 0 0 0                                 |                |
|                                | Animal bites/scratches             | Cat 154 (52.0) 64 (41.6) 21 (13.6) 27 (17.5) 6 (3.9) 14 (9.1) |
|                                | No 118 (39.8)                     | 52 (44.1) 18 (15.3) 22 (18.6) 2 (1.7) 13 (11.0)        |                |
|                                | Insect exposure                    | Mosquitoes 256 (86.5) 106 (41.4) 37 (14.4) 46 (17.9) 8 (3.1) 24 (9.4) |
|                                | Tick 229 (77.4)                   | 96 (41.9) 29 (12.6) 43 (18.7) 10 (4.3) 23 (10.0)        |                |
|                                | Flea 148 (50.0)                   | 66 (44.5) 23 (15.5) 26 (17.5) 7 (4.7) 16 (10.8)        |                |
|                                | Biting Flies 160 (54.0)           | 68 (42.5) 25 (15.6) 27 (16.9) 5 (3.1) 16 (10.0)        |                |
|                                | Lice 38 (12.8)                    | 17 (44.7) 7 (18.4) 3 (7.8) 0 7 (18.4)                    |                |
|                                | Spiders 5 (1.7)                   | 4 (80.0) 1 (20.0) 2 (40.0) 0 1 (20.0)                    |                |
|                                | Sarcoptes mite 3 (1.0)            | 1 (33.3) 0 0 0 0                                         |                |
|                                | Outdoor exposure                  | Hiking 154 (52.0) 66 (42.9) 21 (13.6) 28 (18.2) 5 (3.3) 16 (10.4) |
|                                | Wildlife rescue/rehabilitation     | 22 (7.4) 7 (31.8) 2 (9.1) 2 (9.1) 0 3 (14.3)            |                |
|                                | Hunting 21 (7.1)                  | 9 (42.9) 1 (4.7) 4 (19.0) 0 4 (19.1)                     |                |
|                                | Other 36 (12.2)                   | 16 (44.4) 6 (16.7) 8 (22.2) 2 (5.6) 1 (2.8)             |                |

*Positive sample and exposure categories are not mutually exclusive (i.e., some persons had positive test results by both IFA and PCR, or could have been exposed to both cats and dogs). Median patient ages, for women and men, respectively, were as follows: overall study population, 46.0 and 36.0 y; those with positive results for overall Bartonella, 47.0 and 38.0 y, B. henselae, 44.0 and 41.0 y, B. koehlerae, 49.0 and 40.5 y, B. vinsonii subsp. berkhoffii, 43.0 and 64.0 y, and Bartonella spp., 48.0 and 24.0 y.†Positive PCR results after using Bartonella genus primers but unable to obtain a clean sequence to determine species.
spp. antibodies and bacteremia were 93 (67.4%) and 57 (41.3%), respectively.

Factors Associated with Bartonella spp.

PCRs indicated the following: B. henselae positivity was associated (p<0.05) with blurred vision and numbness (Table 3), patients who had visited a neurologist were more likely than those who had not to be B. henselae positive, older median age was significantly associated with B. koehlerae positivity, and patients who reported paralysis were more likely to be positive for B. vinsonii subsp. berkholffii. No associations were found for self-reported exposures (e.g., insect or animal exposure) and positive PCR for B. henselae, B. koehlerae, or B. vinsonii subsp. berkholffii.

Logistic Regression Analysis

To identify factors associated with PCR positivity for B. henselae or B. koehlerae, we adjusted the models for 3 biological confounders: age, sex, and health status (Table 4). We identified the following factors as associated with B. henselae–positive PCR result: blurred vision (adjusted OR [aOR] 2.37, 95% CI 1.13–4.98), numbness (aOR 2.74, 95% CI 1.26–5.96), and previous consultation with a neurologist (aOR 2.76, 95% CI 1.33–5.73). No self-reported symptoms were significantly associated with PCR positivity for B. koehlerae. However, patients who had visited an infectious disease physician were more likely to have a B. koehlerae–positive PCR result (aOR 1.98, 95% CI 1.05–3.75).

Discussion

We identified unexpectedly high serologic and molecular prevalence for B. henselae, B. koehlerae, and B. vinsonii subsp. berkholffii in patients who had been examined by a rheumatologist, of whom more than half reported a prior diagnosis of Lyme disease, bartonellosis, or babesiosis. However, the diagnostic criterion upon which these infections were based was not available for review because all prior diagnoses were self-reported. Overall, 185 (62.5%) of 296 patients had antibodies to B. henselae, B. koehlerae, or B. vinsonii subsp. berkholffii, and 122 (41.1%) were positive for Bartonella spp. according to PCR. In most instances, DNA sequencing of the amplified product facilitated identification of the infecting species. The prevalence of antibodies against Bartonella spp. (93 [67.4%]) and bacteremia (57 [1.3%]) among 138 patients with a prior diagnosis of Lyme disease did not differ from that of the overall study population. Because our analysis was restricted to patients selected by a rheumatologist practicing in a Lyme disease–endemic region, extrapolations to other regions or other rheumatology practices might not be applicable. Also, because the survey was self-administered, objective confirmation of symptoms, conditions, and diagnoses was not always possible; therefore, responses might have been subject to respondent bias. Similarly, because responses associated with symptoms, conditions, and exposures might have occurred over a protracted time, survey responses might also be subject to recall bias.

Despite these study limitations, B. henselae infections seemed to be more common in patients who reported blurred vision, numbness in the extremities, and previous consultation with a neurologist before referral.

![Figure 1. Bartonella spp. PCR results for the 15 most frequently reported previous diagnoses. OA, osteoarthritis; RA, rheumatoid arthritis.](image1)

![Figure 2. Bartonella PCR amplification results from blood, serum, and enrichment blood culture with the Bartonella α Proteobacteria growth medium. Of 296 patients, 120 had positive PCR results in 1 component. Two patients, who had positive PCR results only after enrichment culture incubation and subculture onto agar, are not included. Each circle represents Bartonella PCR amplification results from blood, serum, or after enrichment blood culture. Each number represents the total (%) positive for each of the 4 possibilities within each of the 3 circles. For example, only 3 (1%) patients had positive results from blood, serum, and enrichment blood culture.](image2)
to the rheumatologist. In a case series of 14 patients, the following were reported by 50% of patients infected with a *Bartonella* species, specifically *B. henselae*, *B. vinsonii* subsp. *berkhoffii*, or both: memory loss, numbness or a loss of sensation, balance problems, and headaches (10). Another 6 *B. henselae*-bacteremic patients reported seizures, ataxia, memory loss, and/or tremors; 1 of these patients was co-infected with *B. vinsonii* subsp. *berkhoffii*, and another was positive for *B. henselae* by PCR after enrichment of cerebrospinal fluid in BAPGM (23). An enrichment culture approach also identified an association between intravascular infection with *B. vinsonii* subsp. *berkhoffii* genotype II and *B. henselae* and neurologic symptoms in a veterinarian and his daughter (12). Symptoms in the father included progressive weight loss, muscle weakness, and lack of coordination; symptoms in

### Table 2. Test results for *Bartonella* spp. in 296 patients examined by a rheumatologist, Maryland–Washington, DC, USA, August 25, 2008–April 1, 2009 *

| Bartonella sp | IFA+/PCR– | IFA+/PCR– | IFA+/PCR+ | IFA+/PCR+ |
|--------------|-----------|-----------|-----------|-----------|
| *B. henselae* | 196       | 60        | 7         | 3         |
| *B. koehlerae* | 177       | 65        | 24        | 29        |
| *B. vinsonii* subsp. *berkhoffii* | 141       | 145       | 3         | 7         |
| Genotype I   | 217       | 75        | 2         | 1         |
| Genotype II  | 189       | 101       | 9         | 5         |
| Genotype III | 213       | 82        | 0         | 0         |

IFA, indirect immunofluorescent antibody results obtained by using *B. henselae*, *B. koehlerae*, and *B. vinsonii* subsp. *berkhoffii* antigens; PCR, results obtained after PCR amplification by using *Bartonella* intergenic spacer primers, followed by attempted DNA sequencing of each amplicon.

### Table 3. Factors associated with *Bartonella* spp. positivity by PCR, among 296 patients examined by a rheumatologist, Maryland–Washington, DC, USA, August 25, 2008–April 1, 2009 *

| Variable                      | *B. henselae*, no. (%) | *B. koehlerae*, no. (%) | *B. vinsonii* subsp. *berkhoffii*, no. (%) |
|-------------------------------|------------------------|-------------------------|--------------------------------------------|
|                               | Positive, n = 40       | Negative, n = 256       | Positive, n = 10                          |
|                               | positive, n = 242       | negative, n = 286       | no. (%)                                   |
| **Signs or symptoms**         |                        |                         |                                            |
| Fatigue                       | 38 (95.0)              | 226 (88.3)              | 48 (88.9)                                 |
| Headache                      | 25 (62.5)              | 155 (60.5)              | 32 (59.2)                                 |
| Difficulty remembering        | 32 (80.0)              | 174 (84.5)              | 38 (70.4)                                 |
| Confusion                     | 26 (65.2)              | 132 (61.5)              | 29 (53.7)                                 |
| Disorientation                | 18 (45.0)              | 82 (35.5)               | 14 (29.6)                                 |
| Irritability                  | 30 (75.0)              | 153 (69.7)              | 32 (59.3)                                 |
| Blurred vision                | 23 (57.5)              | 100 (43.9)              | 23 (42.6)                                 |
| Eye pain                      | 12 (33.3)              | 70 (29.2)               | 13 (27.1)                                 |
| Sleeplessness                 | 7 (19.4)               | 46 (18.5)               | 14 (29.2)                                 |
| Insomnia                      | 17 (47.2)              | 132 (53.2)              | 21 (43.7)                                 |
| Muscle weakness               | 28 (70.0)              | 161 (62.9)              | 21 (43.7)                                 |
| Paralysis                     | 3 (7.5)                | 13 (5.1)                | 3 (5.6)                                   |
| Muscle pain                   | 31 (77.5)              | 176 (68.7)              | 36 (66.7)                                 |
| Numbness                      | 28 (70.0)              | 128 (50.0)              | 25 (46.3)                                 |
| Joint pain                    | 31 (77.5)              | 199 (77.3)              | 41 (75.9)                                 |
| Chronic fatigue               | 27 (67.5)              | 180 (70.3)              | 37 (68.5)                                 |
| Bowel/bladder dysfunction      | 17 (42.5)              | 95 (37.1)               | 19 (35.2)                                 |
| Shortness of breath           | 19 (47.5)              | 98 (38.3)               | 21 (38.9)                                 |
| Poor appetite                  | 8 (20.0)               | 75 (29.3)               | 12 (22.2)                                 |
| Weight loss                   | 7 (17.5)               | 52 (20.3)               | 6 (11.1)                                  |
| Depression                    | 20 (50.0)              | 126 (49.2)              | 28 (51.9)                                 |
| Syncope                       | 4 (10.0)               | 41 (16.0)               | 8 (14.8)                                  |
| Consultation with neurologist | 23 (57.5)              | 87 (33.9)               | 22 (40.7)                                 |
| Consultation with infectious disease physician | 16 (40.0) | 104 (40.6) | 29 (53.7) |

*Median ages, compared by using Wilcoxon rank-sum test, for positive and negative results, respectively, were *B. henselae*, 42.5, 44.0, p = 0.43; *B. koehlerae*, 48.0, 43.0, p = 0.03; and *B. vinsonii* subsp. *berkhoffii*, 46.5, 44.0, p = 0.64.

†Results of *χ*² analysis (Fisher exact test used when expected cell value <5).
the daughter were headaches, muscle pain, and insomnia. For each patient, after repeated courses of antimicrobial drugs, blood cultures became negative, antibody titers decreased to nondetectable levels, and all neurologic symptoms resolved.

Although no symptoms were statistically associated with *B. koehlerae* infection, patients infected with *B. koehlerae* were more likely to have previously consulted an infectious disease physician. Of the 54 *B. koehlerae* patients with a positive PCR result, 54% reported a prior diagnosis of Lyme disease (n = 25), bartonellosis (n = 3), or babesiosis (n = 1). Fatigue, insomnia, memory loss, joint and muscle pain were frequent complaints among those with a positive PCR result for *B. koehlerae*, but these symptoms did not differ in frequency from those in patients with negative PCR. Similar symptoms were previously reported in a small case series involving *B. koehlerae*—bacteremic patients (13). Peripheral visual deficits, sensory loss, and hallucinations resolved in a young woman after antimicrobial drug treatment for *B. koehlerae* infection (30). Because of the small number of patients with positive PCR results for *B. vinsonii* subsp. *berkhoffii*, we restricted the multivariate analysis to those with positive results for *B. henselae* and *B. koehlerae*. Because limited sample size affected our ability to conduct multivariate analysis to control for potential confounders for *B. vinsonii* subsp. *berkhoffii* positivity, the χ² associations with *B. vinsonii* subsp. *berkhoffii* positivity should be interpreted with caution.

Although the pathogenic relevance of the high *Bartonella* spp. seroprevalence and bacteremia in this patient population are unclear, these results justify additional prospective studies involving more narrowly defined patient and control populations. Of the 92 patients infected with *B. koehlerae*, *B. henselae*, or *B. vinsonii* subsp. *berkhoffii*, 69 (75%) had at least 1 discordant IFA assay result for *Bartonella* spp. antigen seroreactivity and only 34 (30.6%) had a concordant species-specific PCR and IFA result. Also, consistent with previous study findings (15), the PCRs depicted in Figure 2 illustrate an increased likelihood of positivity if blood, serum, and enrichment blood cultures are independently tested. According to these and previous results (7,18,31,32), a subset of *Bartonella* spp.—bacteremic patients could be anergic and might not produce a detectable IFA response, or alternatively, the substantial antigenic variation among various *Bartonella* strains might result in false-negative IFA assay results for some patients. In a study on *Bartonella* serology conducted by the Centers for Disease Control and Prevention, IFA cross-reactivity among *Bartonella* species occurred in 94% of patients with suspected cat-scratch disease (33). Despite the lack of concordance between serologic results and BAPGM enrichment PCR results, most (185 [62.5%]) patients in our study were seroreactive to *Bartonella* spp., suggesting prior exposure to ≥1 *Bartonella* spp. Because serologic cross-reactivity to *Chlamydia* spp. and *Coxiella burnetii* antigens has been reported, exposure to these or other organisms might have contributed to the high seroprevalence. In a previous study involving 32 healthy volunteers and patients at high risk for *Bartonella* spp. bacteremia, seroprevalence rates for *B. henselae*, *B. koehlerae* and *B. vinsonii* subsp. *berkhoffii* genotypes I and II were 3.1%, 0%, 0%, and 50%, respectively, for the healthy population compared with 15.6%, 9.2%, 19.8%, and 28.1%, respectively, for the high-risk population (15). Although in that study and the study reported here, the same test antigens and identical IFA assays were used and the same research technologist interpreted the results, the overall seroprevalence in the study reported here was higher than that among high-risk patients with extensive arthropod or animal contact (49.5%) and differed substantially from serologic results from healthy volunteers (15). However, in the study reported here, a large portion of the population (34.5%) was also seroreactive to *B. vinsonii* *berkhoffii* genotype II. Immunophenotypic properties giving rise to seroreactivity to this particular antigen among healthy control and patient populations have not been clarified but could be related to polyclonal B-cell activation, commonly found in patients with rheumatologic or chronic inflammatory diseases.

It is becoming increasingly clear that no single diagnostic strategy will confirm infection with a *Bartonella* sp. in immunocompetent patients. Before the current study, we primarily used BAPGM enrichment blood cultures and PCR to test symptomatic veterinarians, veterinary technicians, and wildlife biologists, who seem to be at occupational risk for *Bartonella* spp. bacteremia because of animal contact and frequent arthropod exposure (10–15,23). Cats are the primary reservoir hosts for *B. henselae*.
and *B. koehleri*, whereas canids, including dogs, coyotes and foxes, are the primary reservoir hosts for *B. vinsonii* subsp. *berkhoffii* (4, 6, 29, 34). Although infrequent when compared with cat transmission of *B. henselae* resulting in classical cat-scratch disease, dogs have been implicated in the transmission of *B. vinsonii* subsp. *berkhoffii* and *B. henselae* to humans (35, 36). The predominant symptoms reported among occupationally at-risk patient populations have included severe fatigue, neurologic and neurocognitive abnormalities, arthralgia, and myalgia (10–13, 23). In the study reported here, dog (85%) and cat (68%) contact were reported by most respondents; however, no associations were found between infection with a *Bartonella* sp. and contact with a specific animal. Similarly, exposure to mosquitoes, ticks, fleas, and biting flies were all reported by >50% of the study population. The results of this study support documentation of *Bartonella* spp. bacteremia in patients seen by a rheumatologist in a Lyme disease–endemic area and provides the basis for future studies to ascertain the prevalence of *Bartonella* spp. in patients with rheumatic and neurologic symptoms.

This study was supported in part by the state of North Carolina, a grant from the American College of Veterinary Internal Medicine Foundation, and a monetary donation from Bayer Animal Health.

Dr Maggi is a research assistant professor in the Department of Clinical Sciences at North Carolina State University College of Veterinary Medicine. His research has focused on the development of novel or improved molecular diagnostic and culture methods for detection of *Bartonella* spp. infections in animals and humans.

E.B.B., in conjunction with Sushama Sontakke and North Carolina State University, holds US Patent No. 7,115,385, Media and Methods for Cultivation of Microorganisms, which was issued October 3, 2006. E.B.B. is chief scientific officer for Galaxy Diagnostics, a newly formed company that provides diagnostic testing for the detection of *Bartonella* species infection in animals and human patients. R.G. Maggi has lead research efforts to optimize the BAPGM platform and is the scientific technical advisor for Galaxy Diagnostics. R. Mozayeni was the attending physician for the patients described in this study and has recently joined Galaxy Diagnostics as the chief medical officer. All other authors have no potential conflicts.

References

1. Dehio C. Interactions of *Bartonella henselae* with vascular endothelial cells. Curr Opin Microbiol. 1999;2:78–82. http://dx.doi.org/10.1016/S1369-5274(99)80013-7
2. Kordick DL, Breitschwerdt EB. Persistent infection of pets within a household with three *Bartonella* species. Emerg Infect Dis. 1998;4:325–8. http://dx.doi.org/10.3201/eid0402.980225
3. Kosoy MY, Regnery RL, Tzianabos O, Marston EL, Jones DC, Green D, et al. Distribution, diversity, and host specificity of *Bartonella* in rodents from the southeastern United States. Am J Trop Med Hyg. 1997;57:578–88.
4. Abbott RC, Chomel BB, Kasten RW, Floyd-Hawkins KA, Kikuchi Y, Koehler JE, et al. Experimental and natural infection with *Bartonella henselae* in domestic cats. Comp Immunol Microbiol Infect Dis. 1997;20:41–51. http://dx.doi.org/10.1016/S0147-9571(96)00025-2
5. Boulouis HJ, Chang CC, Henn JB, Kasten RW, Chomel BB. Factors associated with the rapid emergence of zoonotic *Bartonella* infections. Vet Res. 2005;36:383–410. http://dx.doi.org/10.1051/vetres:2005009
6. Chomel BB, Boulouis HJ, Maruyama S, Breitschwerdt EB. *Bartonella* spp. in pets and effect on human health. Emerg Infect Dis. 2006;12:389–94. http://dx.doi.org/10.3201/eid1203.050931
7. Jendro MC, Weber G, Brabant T, Zeidler H, Wöllenhaup J. Reactive arthritis after cat bite: a rare manifestation of cat scratch disease—case report and overview [in German]. Z Rheumatol. 1998;57:159–63. http://dx.doi.org/10.1007/s003930050074
8. Chomel BB, Kasten RW, Sykes JE, Boulouis HJ, Breitschwerdt EB. Clinical impact of persistent *Bartonella* bacteremia in humans and animals. Ann N Y Acad Sci. 2003;990:267–78. http://dx.doi.org/10.1111/j.1749-6632.2003.tb07376.x
9. Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by *Bartonella* species. Antimicrob Agents Chemother. 2004;48:1921–33. http://dx.doi.org/10.1128/AAC.48.6.1921-1933.2004
10. Breitschwerdt EB, Maggi RG, Duncan AW, Nicholson WL, Hegarty BC, Woods CW. *Bartonella* species in blood of immunocompetent persons with animal and arthropod contact. Emerg Infect Dis. 2007;13:938–41.
11. Breitschwerdt EB, Maggi RG, Farmer P, Mascarelli PE. Molecular evidence of perinatal transmission of *Bartonella vinsonii* subsp. *berkhoffii* and *Bartonella henselae* to a child. J Clin Microbiol. 2010;48:2289–93. http://dx.doi.org/10.1128/JCM.00326-10
12. Breitschwerdt EB, Maggi RG, Lantos PM, Woods CW, Hegarty BC, Bradley JM. *Bartonella vinsonii* subsp. *berkhoffii* and *Bartonella henselae* bacteremia in a father and daughter with neurological disease. Parasites & Vectors. 2010;3:29. http://dx.doi.org/10.1186/1756-3305-3-29
13. Breitschwerdt EB, Maggi RG, Mozayeni BR, Hegarty BC, Bradley JM, Mascarelli PE. PCR amplification of *Bartonella koehleri* from human blood and enrichment blood cultures. Parasites & Vectors. 2010;3:76. http://dx.doi.org/10.1186/1756-3305-3-76
14. Breitschwerdt EB, Maggi RG, Varanat M, Linder KE, Weinberg G. Isolation of *Bartonella vinsonii* subsp. *berkhoffii* genotype II from a boy with epithelioid hemangiendothelioma and a dog with hemangiopericytoma. J Clin Microbiol. 2009;47:1957–60. http://dx.doi.org/10.1128/JCM.00699-09
15. Maggi RG, Mascarelli PE, Pultorak EL, Hegarty BC, Bradley JM, Mozayeni BR, et al. *Bartonella* spp. bacteremia in high-risk immunocompetent patient. Diagn Microbiol Infect Dis. 2011;71:430–7. http://dx.doi.org/10.1016/j.diagmicrobio.2011.09.001
16. Al-Matar MJ, Petty RE, Cabral DA, Tucker LB, Peyvandi B, Prendiville J, et al. Rheumatic manifestations of *Bartonella* infection in 2 children. J Rheumatol. 2002;29:184–6.
17. Giliadi M, Maman E, Paran D, Bicksel J, Comaneshter D, Avidor B, et al. Cat-scratch disease–associated arthropathy. Arthritis Rheum. 2005;52:3611–7. http://dx.doi.org/10.1002/art.21411
18. Hayem F, Chacar S, Hayem G. *Bartonella henselae* infection mimicking systemic onset juvenile chronic arthritis in a 2½-year-old girl. J Rheumatol. 1996;23:1263–5.
19. Maman E, Bicksel J, Ephros M, Paran D, Comaneshter D, Metzker- Cotter E, et al. Musculoskeletal manifestations of cat scratch disease. Clin Infect Dis. 2007;45:1535–40. http://dx.doi.org/10.1086/523587
20. Tsukahara M, Tsuneoka H, Tateishi H, Fujita K, Uchida M. *Bartonella* infection associated with systemic juvenile rheumatoid arthritis. Clin Infect Dis. 2001;32:E22–3. http://dx.doi.org/10.1086/317532
21. Dillon B, Cagney M, Manoliotis N, Iredell JR. Failure to detect *Bartonella henselae* infection in synovial fluid from sufferers of chronic arthritis. Rheumatol Int. 2000;19:219–22. http://dx.doi.org/10.1007/PL00006854
22. Breitschwerdt EB, Suksawat J, Chomel B, Hegarty BC. The immunologic response of dogs to *Bartonella vinsonii* subspecies *berkhoffii* antigens: as assessed by Western immunoblot analysis. J Vet Diagn Invest. 2003;15:349–54. http://dx.doi.org/10.1177/104063870301500408
23. Breitschwerdt EB, Maggi RG, Nicholson WL, Cherry NA, Woods CW. *Bartonella* sp. bacteremia in patients with neurological and neurocognitive dysfunction. J Clin Microbiol. 2008;46:2856–61. http://dx.doi.org/10.1128/JCM.00832-08
24. Diniz PP, Maggi RG, Schwartz DS, Cadenas MB, Bradley JM, Hegarty B, et al. Canine bartonellosis: serological and molecular prevalence in Brazil and evidence of co-infection with *Bartonella henselae* and *Bartonella vinsonii* subspp. *berkhoffii*. Vet Res. 2007;38:697–710. http://dx.doi.org/10.1051/vetres:20070023
25. Duncan AW, Maggi RG, Breitschwerdt EB. A combined approach for the enhanced detection and isolation of *Bartonella* species in dog blood samples: pre-enrichment liquid culture followed by PCR and subculture onto agar plates. J Microbiol Methods. 2007;69:273–81. http://dx.doi.org/10.1016/j.mimet.2007.01.010
26. Maggi RG, Duncan AW, Breitschwerdt EB. Novel chemically modified liquid medium that will support the growth of seven *Bartonella* species. J Clin Microbiol. 2005;43:2651–5. http://dx.doi.org/10.1128/JCM.43.6.2651-2655.2005
27. Cadenas MB, Bradley J, Maggi RG, Takara M, Hegarty BC, Breitschwerdt EB. Molecular characterization of *Bartonella vinsonii* subspp. *berkhoffii* genotype III. J Clin Microbiol. 2008;46:1858–60. http://dx.doi.org/10.1128/JCM.02456-07
28. Maggi RG, Breitschwerdt EB. Potential limitations of the 16S–23S rRNA intergenic region for molecular detection of *Bartonella* species. J Clin Microbiol. 2005;43:1711–6. http://dx.doi.org/10.1128/JCM.43.3.1171-1176.2005
29. Maggi RG, Chomel B, Hegarty BC, Henn J, Breitschwerdt EB. A *Bartonella vinsonii* *berkhoffii* typing scheme based upon 16S–23S ITS and Pap31 sequences from dog, coyote, gray fox, and human isolates. Mol Cell Probes. 2006;20:128–34. http://dx.doi.org/10.1016/j.mcp.2005.11.002
30. Breitschwerdt EB, Mascarelli PE, Schweickert LA, Maggi RG, Hegarty BC, Bradley JM, et al. Hallucinations, sensory neuropathy, and peripheral visual deficits in a young woman infected with *Bartonella koehlerae*. J Clin Microbiol. 2011;49:3415–7. http://dx.doi.org/10.1128/JCM.00833-11
31. Diniz PP, Wood M, Maggi RG, Sontakke S, Stepnik M, Breitschwerdt EB. Co-isolation of *Bartonella henselae* and *Bartonella vinsonii* subspp. *berkhoffii* from blood, joint and subcutaneous seroma fluids from two naturally infected dogs. Vet Microbiol. 2009;138:368–72. http://dx.doi.org/10.1016/j.vetmic.2009.01.038
32. Jones SL, Maggi R, Shuler J, Alward A, Breitschwerdt EB. Detection of *Bartonella henselae* in the blood of 2 adult horses. J Vet Intern Med. 2008;22:495–8. http://dx.doi.org/10.1111/j.1939-1676.2008.0043.x
33. Dalton MJ, Robinson LE, Cooper J, Regnery RL, Olson JG, Childs JE. Use of *Bartonella* antigens for serologic diagnosis of cat-scratch disease at a national referral center. Arch Intern Med. 1995;155:1670–6. http://dx.doi.org/10.1001/archinte.1995.00430150164017
34. Breitschwerdt EB, Kordick DL. *Bartonella* infection in animals: carriership, reservoir potential, pathogenicity, and zoonotic potential for human infection. Clin Microbiol Rev. 2000;13:428–38. http://dx.doi.org/10.1128/CMR.13.3.428-438.2000
35. Keret D, Giladi M, Kletter Y, Wientroub S. Cat-scratch disease osteomyelitis from a dog scratch. J Bone Joint Surg Br. 1998;80:766–7. http://dx.doi.org/10.1302/0301-620X.80B5.80B5.8823
36. Tsukahara M, Tsuneoka H, Iino H, Ohno K, Murano I. *Bartonella henselae* infection from a dog. Lancet. 1998;352:1682. http://dx.doi.org/10.1016/S0140-6736(05)61455-9

Address for correspondence: Edward B. Breitschwerdt, College of Veterinary Medicine, North Carolina State University, 1060 William Moore Dr, Raleigh, NC 27607, USA; email: ed_breitschwerdt@ncsu.edu

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

Get the content you want delivered to your inbox.